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mated, where EQ-5D was regressed on 1) eight SF-36 scores; 2) as per 1) plus squared 
and pair-wise interaction terms, 3) as per 1) plus clinical characteristics; and 4) as 
per 3) plus squared and pair-wise interaction terms, respectively. Model 2 and 4 were 
developed by using stepwise regression analyses. Model goodness of fit was examined 
by using Akaike information criterion (AIC), R2, and adjusted R2. Predictive perfor-
mance was evaluated by using root mean square error (RMSE). Results: Model 1 with 
eight SF-36 scores explained more than 59% of the variation in EQ-5D utility values. 
The best-performing model based on goodness of fit and predictive performance was 
model 4 (AIC= ◽-200.4, R2= 0.767, adjusted R2= 0.709, RMSE= 0.090). The model included 
four SF-36 scores (GH, MH, PF, and RP), five squared terms, twelve pair-wise interaction 
terms, and log transformed simplified disease activity index (SDAI). Also model 2, 
which included no clinical characteristics, had similar predictive ability (AIC= ◽-195.0, 
R2= 0.764, adjusted R2= 0.699, RMSE= 0.093). ConClusions: EQ-5D utility values can be 
predicted from SF-36 scores and SDAI with Japanese patients with RA. The mapping 
model can be applied to SF-36 datasets to produce utility scores for economic evalua-
tion of RA treatments from the perspective of Japan health care system.
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objeCtives: Rheumatoid arthritis is (RA) associated with numerous comorbidities 
that have major impacts on patients’ quality of life. The purpose of this study is 
of twofold, first, to measure the health related utilities on patients with RA using 
time trade-off (TTO) and EQ-5D and to examine how these different measures were 
related to a disease specific measure, Health Assessment Questionnaire (HAQ) and 
disability level of RA. Second, to investigate absenteeism and presenteeism using 
Work Productivity and Activity Impairment Questionnaire for Patients with RA 
(WPAI-RA). Methods: Face-to-face patient interviews on patients with mild RA 
(DAS < 3.2), moderate RA (3.2< = DAS< 5.1) and severe RA (DAS> = 5.1) have been car-
ried out since June 2013 at rheumatology outpatient clinics at four hospitals located 
in northern, central and southern Taiwan, and will be continued until the desired 
sample size of 120 is attained. Health state utilities were elicited using time trade-
off (TTO), visual analogue scale (VAS) and EQ-5D. Productivity losses and activity 
limitation were measured by WPAI-RA. The mean value of the total HAQ score is 
the mean of the scores for the eight categories: dressing, rising, eating, walking, 
hygiene, reach, grip and usual activities. Results: Based upon the preliminary 
sample collected, the mean age was 54.5 years, mean history of disease was 8.16 
years, and 77% were female in the study patients. The mean health utility was 0.87 
(EQ-5D), 0.72 (VAS) and 0.75 (TTO). The mean value of the total HAQ score is 0.83. 
Employed patients reported 10% reduced work productivity in the previous week, as 
well as 21.0% reduced productivity in daily activities (all patients). ConClusions: 
EQ-5D and VAS are consistent measures for HAQ and have high potentials for use 
in assessing the well-being of the patients with RA in Taiwan. Productivity losses 
associated with absenteeism and presenteeism are substantial.
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objeCtives: For patients with rheumatoid arthritis (RA), convenience, frequency 
of dosing, and invasiveness vary greatly across different administration routes and 
may influence their everyday lives. The objective of this study was to investigate 
the impact of administration method on patients’ quality of life, understand their 
resulting unmet needs, and establish an overall preference for method of admin-
istration for RA treatment. Methods: Patients from France, UK, Germany, Italy, 
Spain, Belgium, Sweden, and The Netherlands diagnosed with RA by a physician and 
taking prescription medication – disease-modifying anti-rheumatic drug (DMARD) 
monotherapy, biologic monotherapy, or DMARD and biologic combination therapy 
– completed a 20-minute online survey. Patients were asked about: 1) benefits and 
drawbacks of their current treatment administration method; 2) their preference 
for twice-daily oral therapy versus injection or intravenous (IV) infusion therapy if it 
met their safety and efficacy expectations; 3) if told by their doctor that they needed 
to change their current RA therapy, would they switch to twice-daily oral tablets, 
injections, or IV infusion if efficacy and safety requirements were met. Results: 
1400 patients were included: n= 250 patients in each of France, UK, Germany, Italy, 
and Spain and n= 50 in each of Sweden, Belgium, and The Netherlands. Oral DMARDs 
were seen as having more benefits and fewer drawbacks than DMARD injections, 
biologic injections, and IV therapy. The majority of patients (79%) would prefer a 
twice-daily oral tablet than an injection or IV infusion (21%) if it met efficacy and 
safety expectations. If told by their doctor that they needed to change their current 
RA therapy, 83% of all patients would prefer switching to twice-daily oral tablets over 
injection (13%) or IV infusion (4%). ConClusions: Oral therapy can meet some of 
the key practical and emotional unmet needs RA patients face with injectable or IV 
infusion therapy, providing efficacy and safety requirements are met.
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half-yearly or yearly) (78%) versus oral (daily, weekly, or monthly) drugs (35%). The 
lowest compliance was observed with daily (24%) and monthly (34%) drugs. Less 
frequently administered drugs (except yearly) had the highest compliance with 
quarterly drugs having 63% and half-yearly drugs 70%. ConClusions: This analy-
sis shows that persistence and compliance to osteoporosis treatment is very low 
in postmenopausal women in Hungary. However, higher persistence and better 
compliance was observed for injectable, less frequently administered drugs, which 
may lead to better outcomes.
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objeCtives: The OS-MMAS is a disease-specific 8 item self-reported measure of 
adherence for osteoporosis patients. This study evaluated the measurement prop-
erties of its French translated version. Methods: A cohort of women aged 55 or 
older, with post-menopausal osteoporosis (PMO) residing in France and treated with 
daily or weekly oral bisphosphonates (OBPs) were selected based on their historical 
data from the French Longitudinal Patient Database; following their visit to one of 
the participating practices. Eligible patients were given an OS-MMAS questionnaire 
for completion at home. Internal consistency was evaluated using the Cronbach’s 
coefficient and construct validity using confirmatory one factor analysis (CFA). 
Convergence validity was assessed using agreement between patients’ medication 
procession ratio (MPR) and their total score from OS-MMAS. To assess reproducibility, 
a subset of respondents received a second questionnaire approximately 3 months 
later. Reproducibility was tested using the intra-class correlation (ICC). Results: 
From a network of 1200 French general practices, 117 participated; 687 eligible 
women visited these practices during the period 20-Jul-2012 to 31-Dec-2012. Of 
these women, 218 (mean 73.2 years; SD= 8.1) completed ≥ 1 OS-MMAS. The 6 and 
12 month MPR was less than 80% for 25.7% patients and 59.1% patients, respec-
tively. Cronbach’s alpha coefficient was 0.76 and varied between 0.71 and 0.79 with 
the deletion of one item. The Chi-Square test of association between MPR (< 80%, 
> 80%) and OS-MMAS scores (< 6; 6-8; 8+) was statistically significant at 6 months 
(p= 0.025), but not at 12 months (p-value= 0.059). CFA reported a standardized root 
mean square residual of 0.06. The ICC on 70 patients was 0.24 with 95% confidence 
interval [0.01-0.45]. ConClusions: This study demonstrated acceptable agreement 
between classification of patient’s adherence to OBPs assessed using French trans-
lated OS-MMAS and that using historical 6 months MPR; but also indicated that the 
construct of the OS-MMAS could be improved.
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objeCtives: To obtain a comprehensive overview of the impact of TNF-inhibitors on 
the components of the burden of Rheumatoid Arthritis (RA) in Germany. Methods: 
A systematic literature research in EMBASE, Medline, grey literature including rheu-
matology congress abstracts (ACR, EULAR, DGRh), German RA registry homepages, 
and the Information System of the Federal Health Monitoring (2002-2012) was per-
formed. Published data on the effect of TNF-inhibitors on mortality, morbidity, and 
health care resource utilization (HCRU) was included. Results: Overall, 15 partially 
overlapping full-text articles (0 mortality, 12 morbidity, 5 HCRU), 6 additional unique 
abstracts excluding encore publications (1 mortality, 4 morbidity, 1 HCRU) and two 
other sources (1 morbidity, 1 HCRU) were included in the final review. Reviewed lit-
erature reported an association of TNF-inhibitor use with a 35% lower mortality rate 
(HR= 0.65; p= 0.0004) compared to synthetic disease modifying antirheumatic drugs 
(DMARDs). Disease severity based on symptoms decreased over time in Germany: the 
chances of reaching DAS28 remission (OR= 1.97; 95%-CI: [1.20-3.21]) and functional 
remission (OR= 2.21; 95%-CI: [1.06-4.63]) were doubled, the odds of functional independ-
ence were quadrupled (OR= 4.09; 95%-CI: [1.80-9.29]) with TNF-inhibitor treatment. 
All SF-36 domains and fatigue scores increased significantly after treatment initia-
tion. TNF-inhibitor treatment is associated with fewer limitations in daily activities 
(OR= 0.77; 95%-CI: [0.65-0.90] and less perseverant limitations (OR= 0.82; 95%-CI: [0.68-
0.98]. Standardized disability pension ratios in patients with biologics use decreased 
over time from 12.5 (2001–2003) to 3.4 (2010-2011). Frequency and average duration of 
hospitalization have fallen from 2001 (19% of patients hospitalized with average dura-
tion of 19 days) to 2011 (12%, 12 days). No HRCU data was available for the outpatient 
sector or surgery. ConClusions: Based on available German data, treatment with 
TNF-inhibitors is associated with lower mortality, increasing likelihood to reach clinical 
remission, better symptom control, functional status, work ability and quality of life.
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objeCtives: To develop a mapping model for estimating EuroQol 5D (EQ-5D) utility 
values from Short Form 36 (SF-36) scores in Japanese patients with rheumatoid arthri-
tis (RA), with or without clinical characteristics. Methods: Linear regression models 
were applied to a cross-sectional data set of 112 patients with RA collected from a 
regional hospital in Niigata prefecture, Japan. Four model specifications were esti-
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nent summary (Wk24: 8.4 and 7.6; Wk48: 8.6 and 8.4) and mental component sum-
mary (Wk24: 5.5 and 3.5; Wk48: 4.8 and 3.2), PsAQoL (Wk24: -4.4 and -3.3; Wk48: -4.8 
and -3.5), and DLQI (Wk24: -6.3 and -5.2; Wk48: -6.2 and -5.6) for CZP 200mg Q2W 
and 400mg Q4W patients, respectively. ConClusions: Improvements in generic 
and disease-specific PROs observed over 24 wks were sustained over 48 wks in 
CZP-treated PsA pts. Improvements were observed regardless of CZP dose regimen.
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objeCtives: To develop a patient-reported outcome (PRO) instrument that can 
be qualified by the Food and Drug Administration (FDA) for use in rheumatoid 
arthritis (RA) randomized controlled trials (RCTs) to support treatment ben-
efit claims. Methods: On August 28, 2012, a consensus development workshop 
was held by the RA Working Group (WG) within the Critical Path Institute’s PRO 
Consortium to identify RA-related PRO concepts to determine their potential role 
in the documentation of treatment benefit in RA RCTs. Key stakeholders partici-
pated in this one-day meeting, including RA patients, representatives from the FDA 
(Division of Pulmonary, Allergy, and Rheumatology Products [DPARP] and Study 
Endpoints and Labeling Development [SEALD]), experts from the American College 
of Rheumatology (ACR), European League Against Rheumatism (EULAR), Outcome 
Measures in Rheumatology (OMERACT), National Institutes of Health (NIH, NIAMS) 
and the pharmaceutical industry (RA WG members). Results: Over the course of 
the workshop, a consensus emerged that there are several outcomes important to 
RA patients not explicitly assessed by the ACR response criteria (i.e., fatigue, stiff-
ness, and social participation). Finally, consensus amongst the various stakeholders 
was reached that any new measure needs to provide information over and above 
what is currently captured by the traditional primary composite endpoints and 
the priority would be to focus on FDA qualification of a PRO measure evaluating 
RA-related fatigue. ConClusions: The RA WG is initiating a collaboration with 
clinical experts through OMERACT to provide an operational definition of fatigue 
and to develop a conceptual framework to support its measurement in clinical trials. 
Following this preliminary step, qualitative and quantitative steps will be launched 
to develop the fatigue measure.
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Osteoarthritis (OA) is the most prevalent musculoskeletal disorder and has been 
associated with poorer quality of life for patients who experience heightened pain 
and decreased functionality. Despite the importance of OA management in clinical 
practice settings, there has been limited evidence confirming the adequacy of pain 
relief in patients with knee OA who take analgesics to manage their symptoms. 
objeCtives: To assess changes in pain relief states in the short run (30 days) and 
evaluate associated changes in outcome measures: SF-12, Brief Pain Inventory (BPI) 
and WOMAC in participants with knee OA. Methods: The Survey of Real World 
Therapies (SORT), a 12-month prospective study across 6 EU countries (N= 1,254), 
enrolled participants > 50 years old with knee OA who were prescribed analgesics. 
Patient-reported outcomes measures were collected at baseline and one month post 
baseline: BPI, SF-12 and WOMAC. Inadequate pain relief (IPR) was defined as BPI 
pain score of “moderate or greater pain” (> 4). Results: A total of 1153 participants 
were included: 67.3% women; mean age 68 years (SD= 9.4); mean OA duration 5.9 
years (SD= 6.2). 54% of participants reported experiencing IPR. After 30 days, 28% 
of participants reported changes in pain relief, which was equally distributed (14% 
each) between the two baseline pain-relief states. Changes in IPR states were sig-
nificantly associated with changes in SF-12 composite summary scores and WOMAC 
subscales. Patients who reported improvements in pain scores showed statistically 
significant improvements in average pain (2.7 points) and both QOL composite 
measures (p< 0.01): WOMAC subscales improvement ranged from 8-11 points and 
the Physical and Mental Component Summaries scores decreased 1.83 and 1.79 
points, respectively. Those who experienced worsening pain had an increase in aver-
age pain of 2.7 points on the BPI. These participants showed statistically significant 
decreases in QOL - WOMAC scores decreased between 4-9 points and PCS and MCS 
scores increased 2.10 and 2.27 points, respectively. ConClusions: Changes in pain 
states were significantly associated with overall quality of life and physical function.
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objeCtives: Osteoarthritis (OA), a degenerative condition of the articular cartilage, 
primarily affects the knee joint and surgery is often required for late-stage patients. 
The number of total knee arthroplasties (TKAs) is expected to grow to 3.48 million 
procedures by 2030 in the US alone. However, the devices lack an ideal safety profile. 
The objective of this study was to examine real-world outcomes among OA patients 
post-knee replacement. Methods: Data from the 2012 U.S. National Health and 
objeCtives: To evaluate the preferences of osteoporotic patients for medication 
attributes in Belgium and Ireland, and to assess whether preferences are transferable 
across these jurisdictions. Methods: A discrete-choice experiment was designed 
in which patients were asked to choose between two unlabelled drug alternatives 
(and an opt-out option), which vary in five attributes: efficacy in reducing the risk of 
fracture, type of potential common side-effects, mode and frequency of administra-
tion and out-of-pocket costs. An efficient experimental design was used to construct 
the sets of treatment options and a mixed logit panel data model was employed to 
estimate patients’ preferences. To assess the significance of the differences between 
countries, a joint model was estimated using interaction terms. Results: A total of 
257 Belgian and 200 Irish osteoporotic patients completed the experiment. In both 
countries, patients preferred a drug treatment with a higher risk reduction and a lower 
cost. They disliked more being at risk of gastro-intestinal disorders than at risk of 
skin reactions and flu-like symptoms and preferred 6-month subcutaneous injection 
compared with weekly oral tablets. In Belgium, patients also preferred oral monthly 
tablet over weekly tablets, while Irish patients preferred yearly intravenous over 
weekly tablets. Some differences between countries were significant. Irish patients 
attached higher value to being at risk for skin reactions or flu-like symptoms, and the 
parameter of yearly intravenous was higher (and significant) in Ireland. In addition, 
higher costs are more acceptable for Irish patients. These differences were generally 
robust in subgroups analyses including patients over 65 years, with prior fracture, high 
income or high education. ConClusions: In this study, the preferences of osteo-
porosis patients for drug therapy did not substantially differ between two European 
countries. Only for levels of some attributes significant differences were observed, 
which could not only be related to health and socio-demographic factors.
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objeCtives: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free 
anti-TNF, on patient-reported outcomes (PROs) in axial spondyloarthritis (axSpA), 
including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), over 
48 weeks (wks) in the RAPID-axSpA trial. Methods: The ongoing RAPID-axSpA trial 
(NCT01087762) is double-blind and placebo (PBO)-controlled to Wk24 and dose-blind 
to Wk48. Patient (pts) fulfilled ASAS criteria and had active axSpA. Pts originally 
randomized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose at 
Wks 0, 2, 4) continued on their assigned dose in dose-blind phase; PBO pts enter-
ing dose-blind phase were re-randomized to CZP loading dose followed by CZP 
200mg Q2W or 400mg Q4W. We report efficacy data for the full analysis set (FAS) 
originally randomized to CZP. PRO endpoints included physical function (BASFI), 
total spinal pain, fatigue (from BASDAI), ASQoL, Sleep Problems Index II domain 
of MOS Sleep scale, and SF-36. Missing data were imputed by LOCF. Results: Of 
111 and 107 pts randomized to CZP 200mg Q2W and 400mg Q4W, 105(94.6%) and 
98(91.6%) completed the double-blind period, and 98(88.3%) and 93(86.9%) completed 
the dose-blind period. Rapid improvements from baseline to Wk24 were maintained 
to Wk48, for both CZP 200mg Q2W and 400mg Q2W, in total spinal pain (Wk24: -3.3 
and -3.2; Wk48: -3.6 and -3.5), fatigue (Wk24: -2.6 and -2.8; Wk48: -2.8 and -2.9), BASFI 
(Wk24: -2.4 and -2.3; Wk48: -2.6 and -2.4), ASQoL (Wk24: -5.1 and -5.1; Wk48: -6.0 and 
-5.6) and sleep (Wk24: -12.7 and -12.9; Wk48: -14.7 and -14.2). CZP-treated pts also 
maintained improvements in SF-36 components and domains. Similar outcomes 
were seen in AS and nr-axSpA populations. ConClusions: Improvements in PROs 
observed with both CZP dosing regimens were maintained over 48 wks, including 
those in pain, fatigue, physical function and HRQoL. Maintenance was observed in 
both AS and nr-axSpA pts.
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objeCtives: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free 
anti-TNF, on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) over 
48 weeks (wks) in the RAPID-PsA trial. Methods: The ongoing RAPID-PsA trial 
(NCT01087788) is double-blind and placebo-controlled to Wk24 and dose-blind to 
Wk48. Patients (pts) had active PsA and had failed ≥ 1 DMARD. Pts originally rand-
omized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose at Wks 
0, 2, 4) continued on their assigned dose in dose-blind phase; placebo pts entering 
dose-blind phase were re-randomized to CZP loading dose followed by CZP 200mg 
Q2W or 400mg Q4W. We report efficacy data for the randomised set (RS) of pts 
originally randomized to CZP. Mean changes from baseline in patient assessment of 
pain (VAS), fatigue assessment scale (NRS), HAQ-DI, SF-36, PsAQoL and Dermatology 
Life Quality Index (DLQI) were assessed with LOCF imputation. Results: Of 138 
and 135 pts randomized to CZP 200mg Q2W and 400mg Q4W, 128 (92.8%) and 120 
(88.9%) completed the double-blind period, and 123 (89.1%) and 114 (84.4%) com-
pleted the dose-blind period, respectively. Rapid improvements from baseline to 
Wk24 observed in double-blind period were maintained to Wk48 for pain (Wk24: 
-28.6 and -28.4; Wk48: -31.6 and -29.5), fatigue (Wk24: -2.2 and -1.9; Wk48: -2.4 and 
-2.0), HAQ-DI (Wk24: -0.52 and -0.43; Wk48: -0.56 and -0.49), SF-36 physical compo-
